)
Sysmex (6869) investor relations material
Sysmex Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Net sales for the first quarter rose to ¥130.6 billion, up 23.6% year-on-year, with operating profit at ¥14.8 billion, up 39.5%, and profit attributable to owners at ¥8.6 billion, up 90.9%, driven by strong growth in the Americas, Japan, and yen depreciation.
Significant sales growth in hematology, especially in the Americas, and solid performance in EMEA and AP regions; China declined 33.8% as forecast.
Higher profits resulted from increased sales and the elimination of prior-year one-time inventory revaluation factors.
Cash flows from operating activities reached ¥35.5 billion, with free cash flow at ¥17.0 billion, both showing substantial year-over-year increases.
SG&A and R&D expenses increased due to business expansion but remained under control.
Financial highlights
Operating margin improved to 11.3%, up 1.2 percentage points year-on-year, with cost of sales at ¥64.3 billion (49.3% of sales), SG&A at ¥42.6 billion (32.6%), and R&D at ¥7.2 billion (5.5%).
Profit attributable to owners margin rose to 6.7% from 4.3% year-on-year.
Basic EPS increased to ¥14.17 from ¥7.30 year-on-year.
Cash and cash equivalents increased by ¥29,517 million to ¥113,634 million.
Exchange rates: 1 USD = ¥159.3, 1 EUR = ¥185.3, 1 CNY = ¥23.4.
Outlook and guidance
First-half forecast revised upward: net sales ¥265.0 billion (+14.0% YoY), operating profit ¥25.0 billion, profit attributable to owners ¥15.0 billion, reflecting strong Americas performance and FX trends.
Full-year forecast: net sales ¥545.0 billion (+9.0% YoY), operating profit ¥60.0 billion (+15.8%), profit attributable to owners ¥37.0 billion (+4.4%), with interim dividend forecast raised to ¥20.00 per share and annual to ¥40.00 per share.
One-time expenses related to a business review may be incurred in Q2 and are factored into forecasts.
China sales expected to decline 20% year-on-year for the full year, with gradual easing of negative impacts in the second half.
Guidance may be updated pending regulatory and business developments in China.
- Record FY2024 results underpin FY2025 growth guidance.6869
Q4 2024 - Targets ¥600B sales, 12%+ ROE by FY2029, driven by diagnostics, AI, and digital transformation.6869
Investor update - Global diagnostics leader drives growth through innovation, emerging markets, and new businesses.6869
Investor presentation - Profit and sales fell on China weakness, but global growth and higher dividends are forecast.6869
Q4 2026 - Profits fell on China and Japan weakness, but EMEA and Americas segments showed strong growth.6869
Q3 2026 - Profits fell on lower sales in Japan and China, but global expansion and new business support growth.6869
Q2 2026 - Profits and sales fell sharply, but full-year guidance and dividend plans remain intact.6869
Q1 2026 - Sales and profits surged, prompting an upward revision to full-year guidance.6869
Q2 2025 - Record Q1 sales and profit growth driven by global reagent demand and new product launches.6869
Q1 2025
Next Sysmex earnings date
Next Sysmex earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)